Showing results (2751-2760 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|May 29, 2023
A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with MelanomaElizabeth I Buchbinder, Anita Giobbie-Hurder, Rizwan Haq, et al.
Investigational New Drugs|May 26, 2023
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cellsMinhong Tang, John Crown, Michael J Duffy
Investigational New Drugs|October 21, 2024
Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish modelsSalma Begum, Scheldon D Irvin, Carol K Cox, et al.
Investigational New Drugs|October 26, 2024
A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapySatoshi Hamauchi, Hirofumi Yasui, Tomoya Yokota, et al.
Investigational New Drugs|March 14, 2026
Crocetin suppresses colorectal cancer progression by targeting TGM2 and inhibiting the JAK2/STAT3 pathwayShuo Chen, Weijun Su, Kai Wang, et al.
Investigational New Drugs|April 22, 2026
Spatial blueprint of colorectal cancer identifies Hypoxic CAF program that orchestrates Go-or-Grow decisions and predicts outcomesMingkai Chen, Juan Yang, Jin Wang, et al.
Investigational New Drugs|May 2, 2026
Hedgehog Inhibitor and Paclitaxel: A Phase I Trial of the Oral Hedgehog inhibitor Taladegib in Combination with Weekly Paclitaxel in Patients with Advanced Solid TumoursRosalind Glasspool, Sarah Patricia Blagden, Michelle Lockley, et al.
Investigational New Drugs|June 27, 2023
Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort studyXue Wang, Jinxiang Huang, He Huang, et al.
Investigational New Drugs|August 5, 2023
Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activationMingzhu Pan, Yali Liu, Tian Sang, et al.
Investigational New Drugs|July 11, 2023
Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective studyChenghao Zhao, Huzheng Yan, Zhanwang Xiang, et al.
Pageof 372